An experimental coronavirus vaccine from drugmaker CanSino Biologics 6185 3.74% Inc. showed promising results in a preliminary human study, a sign that China is advancing toward playing a key early role stopping the global pandemic.
CanSino’s vaccine appeared safe for use and produced an immune response in most of the 108 healthy volunteers, according to the new study published Friday by the journal The Lancet.
It is the second positive but preliminary report this week about one of the most advanced coronavirus vaccines in development. Moderna Inc. said Monday its vaccine also induced an immune response and was generally safe and well-tolerated.
CanSino’s results put it among the front-runners that have emerged from more than 100 coronavirus vaccines in development world-wide.
The phase 1 trial marks just the start of human testing, however. More study will be needed to make sure the vaccine candidate can safely protect people against the coronavirus specifically. Last month, CanSino began a phase 2 trial of the candidate, according to the official Xinhua News Agency.
In the phase 2 trial, researchers plan to test the low and middle doses in about 500 subjects. CanSino said last week Canadian health authorities approved a phase 3 clinical trial in the country.
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.